Accessibility Menu
BIOINVENT AB logo

BIOINVENT AB(OTC) BOVNF

This security has been delisted. This page is retained for historical reference.

BIOINVENT AB last closing stock price
MetricPriceDate
Last closeUSD 3.292026-08-07
BIOINVENT AB stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 3.292026-07-13
1 month+0%USD 3.292025-06-10
3 month+0%USD 3.292025-06-10
Year to date+0%USD 3.292025-06-10
1 year+0%USD 3.292025-06-10
3 year-30.03%USD 4.702023-02-08
5 year-51.92%USD 6.842021-06-29
Since inception-29.28%USD 4.652008-06-19

BOVNF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

BOVNF Financials

Key Financial Metrics (TTM)

Gross Margin

50.57%

Operating Margin

-1568.71%

Net Income Margin

-1529.24%

Return on Equity

-99.58%

Return on Capital

-61.94%

Return on Assets

-117.27%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

SEK 16.44M

Operating Income

-SEK 507.74M

EBITDA

-SEK 483.82M

Operating Cash Flow

-SEK 437.13M

Capital Expenditure

-SEK 4.55M

Free Cash Flow

-SEK 441.68M

Cash & ST Invst.

SEK 337.91M

Total Debt

SEK 21.29M

BIOINVENT AB Performance Analysis

BIOINVENT AB annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 32,226,2291327.2%
20232023-12-31SEK 6,731,479-79.1%
20242024-12-31SEK 4,226,533-37.2%
20252025-12-31SEK 23,094,040446.4%
BIOINVENT AB sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-98.3%
Q42025-12-31-8.8%
Q12026-03-31346.2%
Q22026-06-30-5.8%
BIOINVENT AB annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.07-88.6%
20232023-12-31SEK -0.47592.7%
20242024-12-31SEK -0.6230.5%
20252025-12-31SEK -0.52-16.4%
BIOINVENT AB sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-433.9%
Q42025-12-312.5%
Q12026-03-315.7%
Q22026-06-30-1.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

SEK 12.64M

-93.6%

Gross Profit

SEK 0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

109

N/A

Net Income

-SEK 121.86M

-414.1%

EBITDA

-SEK 119.74M

-405.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

SEK 337.91M

-57.6%

Total Debt

SEK 21.29M

+64.5%

Accounts Receivable

SEK 29.65M

-57.2%

Inventory

SEK 10.04M

+1.5%

Long Term Debt

SEK 12.60M

+230.4%

Short Term Debt

SEK 8.69M

-13.9%

Return on Assets

-1.17%

N/A

Return on Invested Capital

-1.55%

N/A

Free Cash Flow

-SEK 111.64M

-270.7%

Operating Cash Flow

-SEK 110.99M

-1680.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATRXAdhera Therapeutics Inc
$0.00+0.00%
BPMUFBasilea Pharmaceutica AG
$77.40+0.00%
CASIFCASI Pharmaceuticals, Inc.
$0.15+0.00%
CLVLFClinuvel Pharmaceuticals Limited
$5.89-0.51%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.